Head to head
Merck & Co vs Eli Lilly and Co
Side-by-side on the measures that matter, with a plain-English read. Full detail: MRK · LLY
MRK
Merck & Co
145.60+2.26%
1-year price shape — +70% over the period
Quant Rating B · 89/100
vs
LLY
Eli Lilly and Co
1,179.27+0.83%
1-year price shape — +39% over the period
Quant Rating B · 77/100
1-year performance, rebased to 100
Eli Lilly and Co edges it on the scoreable measures. Eli Lilly and Co trades cheapest on trailing earnings; Eli Lilly and Co earns the most per share.
| MRK | LLY | |
|---|---|---|
| Snapshot | ||
| Sector | -- | Drug Manufacturers - General |
| Last price | 145.60 | 1,179.27 |
| Change today | +2.26% | +0.83% |
| 1-year return | +70.3% | +38.7% |
| Market cap | $359.22B | $1.11T |
| 52-week range | 79.67 – 156.00 | 778.93 – 1,292.65 |
| Valuation | ||
| P/E (TTM) | 116.48 | 39.59 |
| P/E percentile, own 5-yr range | 88th | 6th |
| P/B | 8.57 | 32.77 |
| Dividend yield | 2.31% | 0.55% |
| Profitability & growth | ||
| EPS (TTM) | 7.28 | 22.95 |
| Net profit (TTM) | $17.96B | $21.60B |
| Revenue (TTM) | $66.57B | $79.67B |
| Revenue growth (YoY) | +5.1% | +47.7% |
| Gross margin | 73.0% | 83.4% |
| Operating margin | 10.5% | 49.7% |
| Net margin | 4.8% | 33.5% |
| Free cash flow (TTM) | $16.06B | $13.56B |
| Ownership & sentiment | ||
| Institutional ownership | 81.5% | 79.3% |
| Insider activity (12mo) | 41 buy / 8 sell | 37 buy / 13 sell |
| Short interest (% of float) | 1.1% | 0.7% |
| Analyst consensus | 74% buy / 26% hold (19) | 91% buy / 5% hold / 5% sell (22) |
| Analyst price target | $165 (+13%) | $1,383 (+17%) |
| StockVane view | ||
| StockVane Quant Rating | B (89) | B (77) |
| Company | ||
| Employees | 75,000 | 50,000 |
| Founded | 1891 | 1876 |
▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.